AbCellera Biologics Inc vs Invesco Solar ETF — how do they compare? AbCellera Biologics Inc trades at $9.14 (market cap $2.85B), while Invesco Solar ETF trades at $53.29. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | TAN | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $9.76 | $73.95 |
52-Week Low | $2.78 | $36.62 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
TAN trades at $52.75, up 2.93% today amid positive solar sector news. Technical indicators are bearish overall, with moving averages signaling caution and RSI-6 suggesting overbought conditions. Recent tariffs on imported solar products have boosted sentiment, but the ETF faces headwinds from high volatility and regulatory uncertainty.
The outlook is mixed: supportive policies may drive growth, yet valuation concerns and interest rate sensitivity pose risks. Investors should weigh exposure to utility-scale solar growth against sector volatility and top-heavy holdings.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →